跳到正文
原文
The Lancet 柳叶刀· Domenica Lorusso, Jérôme Martin-Babau, Floor Backes, Maria Pilar Barretina Ginesta, Jacob Korach, Shibani Nicum, Julian Wampfler, Jianqing Zhu, Monika Ducceschi, Toon Van Gorp, Magnus Frödin-Bolling, Flora Zagouri, Judith R Kroep, Isabelle Ray-Coquard, Vanda Salutari, Michelle D S Lightfoot, Todd Tillmanns, David M O’Malley, Kosei Hasegawa, Jung-Yun Lee, Gonzalo H Giornelli, Vanessa Samouëlian, Yoland Antill, Jundong Li, Shin Nishio, Jack Junjie Chan, Bradley J Monk, Chenxiang Li, Kristina Woodhouse, Robert Orlowski, Carmen García-Duran, Bhavana Pothuri, TroFuse-005/ENGOT-en23/GOG-3095 Investigators·· 25 天前精选AI 评分85

sacituzumab tirumotecan 与现有治疗选择在复发性子宫内膜癌中的 III 期试验结果

[Articles] Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial

AI 导读

sacituzumab tirumotecan 显著改善了复发性子宫内膜癌患者的无进展生存期和总生存期,优于现有治疗选择,可能成为新标准疗法。

推荐理由

III 期试验显示 sacituzumab tirumotecan 在复发性子宫内膜癌中的疗效优于现有治疗,可能成为新标准疗法。

来源:The Lancet 柳叶刀 · thelancet.com